<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS98600</article-id>
<article-id pub-id-type="doi">10.1101/2020.10.14.338053</article-id>
<article-id pub-id-type="archive">PPR226729</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Shark conservation risks associated with the use of shark liver oil in SARS-CoV-2 vaccine development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Macdonald</surname>
<given-names>Catherine</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soll</surname>
<given-names>Joshua</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Field School, 3109 Grand Ave #154, Miami, FL 33133</aff>
<aff id="A2">
<label>2</label>Rosenstiel School of Marine and Atmospheric Science, University of Miami, 4600 Rickenbacker Causeway, Miami, FL, USA 33149</aff>
<aff id="A3">
<label>3</label>University of Colorado Boulder, Department of Ecology and Evolutionary Biology</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding author: <email>catherine.macdonald@rsmas.miami.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>15</day>
<month>10</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The COVID-19 pandemic may create new demand for wildlife-generated products for human health, including a shark-derived ingredient used in some vaccines. Adjuvants are a vaccine component that increases efficacy, and some adjuvants contain squalene, a natural compound derived from shark liver oil which is found most abundantly in deep-sea sharks. In recent decades, there has been growing conservation concern associated with the sustainability of many shark fisheries. The need for a potentially massive number of adjuvant-containing SARS-CoV-2 vaccines may increase global demand for shark-derived squalene, with possible consequences for shark conservation, especially of vulnerable and understudied deep-sea species. A shift to non-animal-derived sources of squalene, which are similar in cost and identical in effectiveness, or an emphasis on increasing traceability and sustainability of shark-derived squalene from existing well-managed fisheries, could better support conservation and public health goals.</p>
</abstract>
<kwd-group>
<kwd>Squalene</kwd>
<kwd>COVID-19</kwd>
<kwd>SARS-CoV-2</kwd>
<kwd>Shark</kwd>
<kwd>Liver oil</kwd>
<kwd>Vaccines</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p id="P2">Shark populations have historically been exploited for meat, fins, leather, and products derived from their liver oil, including vitamin A and additives to topical cosmetic formulas and lotions (<xref ref-type="bibr" rid="R17">Dent and Clarke, 2015</xref>; <xref ref-type="bibr" rid="R33">Lozano-Grande et al., 2018</xref>). Some historic shark liver oil fisheries have been associated with intense, short-lived periods of exploitation contributing to stock collapses (<xref ref-type="bibr" rid="R47">Stevens et al., 2000</xref>; <xref ref-type="bibr" rid="R30">Kyne and Simpfendorfer, 2007</xref>; <xref ref-type="bibr" rid="R4">Anderson and Waheed, 1999</xref>; <xref ref-type="bibr" rid="R3">Ali and Sinan, 2014</xref>). Sharks, particularly deep-sea species, tend to grow slowly and produce relatively few young, leaving them especially susceptible to overexploitation (<xref ref-type="bibr" rid="R45">Simpfendorfer and Kyne, 2009</xref>). Squalene is a natural polyunsaturated hydrocarbon compound (C<sub>30</sub>H<sub>50</sub>) found in many living organisms that can be refined from shark liver oil. This compound (and its more stable, hydrogenated derivate, squalane) have shown genuine potential to contribute to human health, as an ingredient in vaccines and other pharmaceuticals and dietary supplements (<xref ref-type="bibr" rid="R31">Kim and Karadeniz, 2012</xref>).</p>
<p id="P3">Many shark species, particularly deep-sea sharks, have relatively large livers (up to 20% of animal weight) which serve as a buoyancy control system and critical energy reserve (<xref ref-type="bibr" rid="R51">Vannuccini 1999</xref>; <xref ref-type="bibr" rid="R1">Abel and Grubbs 2020</xref>). A significant portion of liver weight is made up of liver oil (10-70%; <xref ref-type="bibr" rid="R37">Nichols et al., 2001</xref>), and between 15 and 82% of liver oil is squalene (<xref ref-type="bibr" rid="R18">Deprez et al., 1990</xref>; <xref ref-type="bibr" rid="R5">Bakes &amp; Nichols 1995</xref>). Although squalene is produced by a range of animals and plants, shark liver oil has historically been a preferred commercial source based on availability and high yields relative to most plant-derived sources.</p>
<p id="P4">Squalene can be extracted directly from shark liver oil at high purity (&gt;98%) in approximately 10 hours, using a single distillation process in a vacuum at 200-230° C, a faster process producing greater yields than plant-based alternatives (<xref ref-type="bibr" rid="R8">Camin et al., 2010</xref>). Sealed and protected from oxygen and light, squalene has an approximately two-year shelf life, making stable rates of ongoing production important to availability (<xref ref-type="bibr" rid="R8">Camin et al., 2010</xref>). Plant-derived squalene can also be refined to a high level of purity for medical applications, and is made up of C<sub>30</sub>H<sub>50</sub> molecules chemically identical to those from shark-derived sources. Plant-derived squalene has been shown to perform comparably to shark-derived squalene as an ingredient in vaccine adjuvants (<xref ref-type="bibr" rid="R6">Brito et al. 2011</xref>). Accordingly, the FDA is agnostic on the source of squalene and the <italic>Current Good Manufacturing Practice for Finished Pharmaceuticals</italic> only requires that lots of C<sub>30</sub>H<sub>50</sub> be “tested for conformity with all appropriate written specifications for purity, strength, and quality” (2019). Chemical vendors listed on the NIH National Library of Medicine for squalene do not differentiate by squalene origin but instead identify the compound by Chemical Abstract Services (CAS) number 7683-64-9, meaning there are no legal or administrative barriers preventing a shift to plant-derived sources of squalene (<xref ref-type="bibr" rid="R35">National Center for Biotechnology Information, 2020</xref>).</p>
<p id="P5">Shark-derived squalene is a popular ingredient in topical cosmetic formulas and lotions, generating a significant portion of global demand for shark liver oil (<xref ref-type="bibr" rid="R33">Lozano-Grande et al., 2018</xref>; <xref ref-type="bibr" rid="R12">Ducos et al., 2015</xref>). In recent years, however, consumers and non-profit organizations in the United States and Europe have exerted pressure on the cosmetics industry to transition to plant-derived squalene (<xref ref-type="bibr" rid="R13">Consumers unaware of 2013</xref>; <xref ref-type="bibr" rid="R42">Shark Free</xref>). Independent testing by the French non-profit organization Bloom determined most beauty products (&gt;90% of those tested) sold in Europe or the United States no longer contain shark-derived ingredients, although shark-derived squalene remains in common use in beauty products elsewhere (<xref ref-type="bibr" rid="R12">Ducos et al., 2015</xref>). More recent studies have demonstrated the presence of shark DNA, including from Threatened and Endangered species, in some US-sold beauty products as well (<xref ref-type="bibr" rid="R10">Cardeñosa et al., 2017</xref>; <xref ref-type="bibr" rid="R9">Cardeñosa, 2019</xref>).</p>
<sec id="S2">
<label>1.1</label>
<title>Squalene in vaccines</title>
<p id="P6">Squalene is used as an adjuvant, a component of a vaccine that enhances efficacy by increasing human immune response and the potency of antigens, while promoting antigen transport into lymph nodes and uptake in the immune cells (<xref ref-type="bibr" rid="R7">Brito and O’Hagan, 2014</xref>). The inclusion of adjuvants also reduces the volume of antigen needed per vaccine dose through the process of “antigen sparing,” maximizing rates of vaccine production (<xref ref-type="bibr" rid="R48">Tang et al.. 2015</xref>; <xref ref-type="bibr" rid="R40">Schmidt et al. 2016</xref>). Although the primary global demand for shark liver oil in recent years appears to be for use in cosmetics and lotions (<xref ref-type="bibr" rid="R51">Vannuccini 1999</xref>; <xref ref-type="bibr" rid="R33">Lozano-Grande et al., 2018</xref>), the role of shark-derived squalene in vaccine production may represent a potential threat to some vulnerable shark populations, given widespread efforts to rapidly develop and disseminate vaccines in response to the COVID-19 pandemic and the patchwork management approach to global shark fishing limits (<xref ref-type="bibr" rid="R2">Ahn et al., 2020</xref>; <xref ref-type="bibr" rid="R27">Hodgson, 2020</xref>; <xref ref-type="bibr" rid="R16">Davidson et al. 2016</xref>).</p>
<p id="P7">As an ingredient in adjuvants, squalene has been found to be safe and effective in vaccines for the treatment of viruses including H7N9 and H7N7 (Wu et al., 2014), H1N1 (<xref ref-type="bibr" rid="R53">Vesikari et al., 2012</xref>), MERS-CoV (<xref ref-type="bibr" rid="R57">Zhang et al. 2016</xref>), and SARS-CoV (<xref ref-type="bibr" rid="R46">Stadler et al., 2005</xref>). MF59, an adjuvant containing shark-derived squalene, has been used commercially in influenza vaccines (<xref ref-type="bibr" rid="R41">Schultze et al. 2008</xref>; <xref ref-type="bibr" rid="R38">Panatto et al. 2020</xref>) and used or tested in previous vaccines for other coronaviruses (<xref ref-type="bibr" rid="R46">Stadler et al., 2005</xref>; <xref ref-type="bibr" rid="R57">Zhang et al., 2016</xref>).</p>
<p id="P8">A few of the potential SARS-CoV-2 vaccines currently in testing include adjuvants MF59 or AS03, which are known to contain shark-derived squalene (<xref ref-type="bibr" rid="R15">COVID-19 Update 2020</xref>; <xref ref-type="bibr" rid="R25">GlaxoSmithKline aims... 2020</xref>, <xref ref-type="bibr" rid="R54">WHO, 2020</xref>). Per dose, MF59 contains 9.75 mg and AS03 contains 10.68 mg of squalene (<xref ref-type="bibr" rid="R28">Jackson et al., 2015</xref>). Some potential vaccines are being manufactured in bulk before the completion of large-scale safety and efficacy trials (<xref ref-type="bibr" rid="R49">U.S. to Stockpile... 2020</xref>), suggesting that the total number of manufactured doses of various potential vaccines may be far higher than the number ultimately administered. It also remains unknown how frequently revaccination would be necessary if a safe and effective vaccine becomes available (<xref ref-type="bibr" rid="R14">COVID-19 Could Become... 2020</xref>; <xref ref-type="bibr" rid="R21">Ellis, 2020</xref>; <xref ref-type="bibr" rid="R50">Vaccine companies... 2020</xref>), so the scale of possible future demand for squalene as an ingredient in vaccine adjuvants is large but difficult to fully or accurately assess.</p>
<p id="P9">Deep-sea sharks are valued in the shark liver oil trade because they offer greater volumes of liver oil than other species. Relatively little is known about population structure, reproduction, and habitat use of many of these species due to the logistical difficulties of conducting research in deep-sea habitats and a generally low research and management priority (e.g., <xref ref-type="bibr" rid="R36">Neiva et al., 2006</xref>; <xref ref-type="bibr" rid="R30">Kyne and Simpfendorfer, 2007</xref>; <xref ref-type="bibr" rid="R52">Veríssimo et al., 2011</xref>). Most elasmobranchs are slow to mature and reproduce, and deep-sea sharks are particularly so, showing population increase rates of less than half those of continental shelf and pelagic shark species relying on shallower habitats (<xref ref-type="bibr" rid="R45">Simpfendorfer and Kyne, 2009</xref>). Squaloid sharks (species found in order squaliformes) are a preferred source of liver oil and squalene, and include species which are among the slowest growing and latest maturing sharks known (<xref ref-type="bibr" rid="R34">Musick, 2005</xref>). Shark reproductive rates and recovery potential generally decline with increasing depth, and overfished populations of deep-sea shark species may require centuries to recover (<xref ref-type="bibr" rid="R45">Simpfendorfer and Kyne, 2009</xref>). Evidence suggests that even low rates of deep-sea shark exploitation (incidental or targeted) is likely to quickly deplete populations (<xref ref-type="bibr" rid="R45">Simpfendorfer and Kyne, 2009</xref>). For these reasons, deep-sea sharks have been identified as a conservation priority grouping (<xref ref-type="bibr" rid="R19">Dulvy et al., 2014</xref>).</p>
<p id="P10">Assessment of the global conservation status of sharks is complicated by poor catch reporting, challenges with species-level identification, and a lack of baseline data. The reported annual catch of sharks likely substantially underestimates actual total catch (<xref ref-type="bibr" rid="R55">Worm et al., 2013</xref>; <xref ref-type="bibr" rid="R19">Dulvy et al., 2014</xref>). Total catch has been estimated at approximately 100 million animals annually, with an estimate range of 63 to 273 million (<xref ref-type="bibr" rid="R55">Worm et al., 2013</xref>). It is particularly difficult to assess rates of capture for species targeted for products like shark liver oil, for which there is relatively little detailed production or trade information available (<xref ref-type="bibr" rid="R24">Fowler et al., 1997</xref>; <xref ref-type="bibr" rid="R51">Vannuccini, 1999</xref>).</p>
<p id="P11">The global trade in shark liver oil is small compared to that in shark fins or meat, and despite the vulnerability of some target species to overfishing has received relatively little media (<xref ref-type="bibr" rid="R43">Shiffman et al., 2020</xref>) or scientific attention (<xref ref-type="bibr" rid="R17">Dent and Clarke, 2015</xref>). Although there are fisheries in which deep-sea sharks are targeted (see, e.g., <xref ref-type="bibr" rid="R30">Simpfendorfer and Kyne, 2007</xref>), liver oil may also be generated opportunistically from incidental catches in fisheries predominantly targeting other fish, or targeting sharks for other products (e.g., meat, fins). In at least some cases, however, the export value of shark liver oil exceeds that of shark meat, and in some locales the available supply of shark liver oil is insufficient to meet processors’ demand for raw materials (<xref ref-type="bibr" rid="R17">Dent and Clarke, 2015</xref>). A lack of traceability presents a further challenge in assessing the trade in shark liver oil, as the United Nations Food and Agriculture Organization (FAO)’s <italic>Codex Alimentarius</italic> allows for products like squalene to be labelled as originating in the countries in which they were processed even when ingredients (e.g., the liver oil from which the squalene was derived) were produced elsewhere (<xref ref-type="bibr" rid="R22">FAO, 2001</xref>).</p>
<p id="P12">This study provides a basis for beginning to evaluate the range of potential conservation effects of increasing demand for shark-derived squalene as an ingredient in vaccine adjuvants.</p>
</sec>
</sec>
<sec id="S3" sec-type="materials | methods">
<label>2</label>
<title>Materials and methods</title>
<p id="P13">Based on a review of available scientific and management literature, 133 species were identified which are known to be involved in the liver oil trade (<xref ref-type="supplementary-material" rid="SD1">Appendix 1</xref>), including many that are partially reliant on deep-sea habitat &gt;200 m (n=83) or are found exclusively in the deep-sea (n=21). Additional data on the conservation status and population trends of elasmobranch species, primarily sharks, identified as being involved in the liver oil trade were compiled from their most recent IUCN Red List assessments. Available current trade data on the shark liver oil trade was downloaded from the UN FAO FishStat Database (<xref ref-type="bibr" rid="R23">FAO, 2020</xref>). Commercial sources of wholesale quantities of squalene were identified through internet searches and through direct contact with wholesalers to collect pricing, origin, and availability information for both plant- and shark-derived squalene and squalane (its more stable, hydrogenated derivate).</p>
</sec>
<sec id="S4" sec-type="results">
<label>3</label>
<title>Results</title>
<p id="P14">Across elasmobranch species identified as being exploited for shark liver oil, 50% had not been assessed by the IUCN in at least ten years, and 30% were considered Data Deficient (<xref ref-type="fig" rid="F1">Figure 1</xref>; an IUCN Shark Specialist Group reassessment of elasmobranch species is currently underway and expected to be completed in 2020 (<xref ref-type="bibr" rid="R20">Dulvy, 2018</xref>)). One-third of species identified as part of the shark liver oil trade are classified as threatened (Vulnerable, Endangered, or Critically Endangered) according to IUCN Red List criteria (<xref ref-type="fig" rid="F2">Figure 2</xref>). Population trends for 56% of these species are unknown, and 34% are assessed as showing a decreasing trend (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<p id="P15">The most recent FAO data available (2018) showed an increase in reported import and processed production of shark liver oil, with trade volumes reaching 752 tons, the largest reported volume in decades (<xref ref-type="fig" rid="F4">Figure 4</xref>; from 2000-2017, average reported trade volume was under 200 tons annually; <xref ref-type="bibr" rid="R26">Hareide et al., 2007</xref>). Despite this increase, the total value of the shark liver oil trade was reported at 553 000 USD in 2018, the lowest value reported since 1987 (mean annual value from 2000-2017, 1 954 000 USD; <xref ref-type="bibr" rid="R26">Hareide et al. 2007</xref>; <xref ref-type="bibr" rid="R23">FAO, 2020</xref>). Moderate assumptions about oil yield suggest the range of individual animals in the reported global liver oil trade in 2018 falls between 694 848 (large sharks) and 16.35 million (small sharks), with 1.8 million (based on a 20.8 kg median unidentified shark weight; <xref ref-type="bibr" rid="R55">Worm et al. 2013</xref>) as the best supported rough estimate (for yield assumptions see <xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p id="P16">Data collected on the price of shark- and plant-derived squalene showed no clear differences, though products listed as both shark- and plant-derived were commonly available in the wholesale market (<xref ref-type="table" rid="T2">Table 2</xref>). There was significant variability in price across individual sellers (ranging from $20-260/kg for squalene and $10-99.21/kg for squalane). The mean and median price for plant-derived squalene was $40, and the mean price for shark-derived squalene was $45.75 with a median of $48.5/kg (excluding the outlier of $260; including it, the mean price for shark-derived squalene was $76.36, with a median price of $54). The mean price for plant-derived squalane was $53.16/kg (median $48.65/kg), while shark-derived squalane was $45/kg (median $45/kg). These products were identified as being sold from China (67% of products) and the United States (33% of products). Based on these numbers, the estimated potential commercial value of squalene from a single shark ranges from $0.05 (small shark/low yield) to $242.65 (large shark/high yield).</p>
<p id="P17">Given that each vaccine dose requires approximately 10mg of squalene, the mean squalene cost-per-vaccine-dose for shark-derived squalene would be $0.0004575 USD, and for plant-derived, $0.0004 USD—a price difference of $0.0000575 per dose.</p>
</sec>
<sec id="S5" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p id="P18">These results highlight the extent to which liver oil fisheries could affect shark species of conservation concern, and the potential difficulty of detecting these effects because of a lack of information on the volume of liver-oil-associated catch and the absence of population status information for many deep-sea species. The life history characteristics of deep-sea sharks (<xref ref-type="bibr" rid="R45">Simpfendorfer and Kyne, 2009</xref>), insufficient restrictions on exploitation, and declines in availability of shark-derived squalene over time (<xref ref-type="bibr" rid="R44">Sibuyo et al., 2017</xref>) suggest that the trade in shark liver oil, while currently small, has potential to disproportinately harm specific vulnerable elasmobranch species and populations.</p>
<p id="P19">Estimating potential conservation effects is further complicated by the fact that shark species vary greatly in the percentage of their body weight comprised of the liver (from at least 2.9-20%; Vannucini, 1999; <xref ref-type="bibr" rid="R1">Abel and Grubbs, 2020</xref>); in the amount of liver weight made up of oil (ranging from at least 10-70%; <xref ref-type="bibr" rid="R37">Nichols et al., 2001</xref>); and in the yield of squalene from extracted liver oil (a range of at least 15-82%; <xref ref-type="bibr" rid="R18">Deprez et al., 1990</xref>; <xref ref-type="bibr" rid="R5">Bakes &amp; Nichols 1995</xref>). Evidence further suggests animal size, sex, and seasonal and regional factors can also affect yields (<xref ref-type="bibr" rid="R29">Kreuzer and Ahmed, 1978</xref>; <xref ref-type="bibr" rid="R37">Nichols et al., 2001</xref>). Accordingly, it is impossible to calculate an exact effect of increased vaccine-related demand for shark-derived squalene on shark populations.</p>
<p id="P20">We know that fisheries primarily targeting sharks for liver oil exist (e.g., <xref ref-type="bibr" rid="R30">Kyne and Simpfendorfer, 2007</xref>), and that, in many cases, multiple products may be marketed from a single shark (e.g., meat, fins, liver oil, cartilage). Data are not available to assess the volume of liver oil generated globally by directed versus incidental fishing. The effect of increased demand for shark-derived squalene is highly dependent on whether it increases targeting of oil-rich deep-sea sharks, or simply drives increased processing and use of the livers of sharks currently taken for other purposes. Thus, conservation effects of vaccine-related demand for squalene could range from minimal (assuming demand is met by more efficient use of individuals already being landed in well-managed fisheries) to catastrophic for individual species (if demand drives the creation of new targeted fisheries for vulnerable deep-sea species in the absence of limits on fishing and trade).</p>
<p id="P21">The future availability of shark squalene will likely be constrained by shark population declines and by regulatory efforts to conserve sharks, suggesting the prudence of shifting to more stable and sustainable sources. A vaccine supply chain dependent on shark fisheries is subject to disruption if targeted shark populations collapse or new protections are introduced. Plant-derived alternatives to shark-derived squalene are more environmentally sustainable and readily available. Although in the past shark-derived squalene was reported to be significantly less expensive than plant-derived (<xref ref-type="bibr" rid="R8">Camin et al., 2010</xref>), current costs are similar. Non-animal-derived squalene may even be safer for use in some health-related applications because of the reduced risk of contamination with persistent organic pollutants, including polychlorinated biphenyls and organochlorine insecticides, high levels of which have been found in nutritional supplements made from shark liver oil (<xref ref-type="bibr" rid="R39">Rawn et al., 2009</xref>).</p>
<p id="P22">Despite generally comparable costs between shark- and plant-derived squalene, and potential advantages in long-term availability and contaminant levels, non-animal-derived squalene does not appear to be in current use in vaccine production. Consumer and activist pressure could be effective in encouraging pharmaceutical companies to transition to non-animal-derived squalene in adjuvants, for testing for other medical uses, and in nutraceutical products. Demand-driven increases in production of pharmaceutical grade plant-derived alternatives may also incidentally support reduction or elimination of shark-derived squalene in cosmetic formulations. Increased accountability, including product testing to confirm plant origins and transparency within supply chains, would be vital to a transition away from reliance on shark-derived squalene.</p>
</sec>
<sec id="S6" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p id="P23">The mean difference in cost per dose of a potential SARS-CoV-2 vaccine containing squalene derived from plants instead of shark liver oil is -$0.0000575, based on currently available wholesale price information. While commercially available wholesale squalene may not meet the standard of purity needed for pharmaceutical applications, given these values it would cost $20,125.00 less to generate the 350 million doses needed to vaccinate the U.S. population with plant- rather than shark-derived squalene. Doing the same for the global population of 7 billion would save $402,500.00 over use of shark-derived squalene (without accounting for the effects high demand might have on price or availability).</p>
<p id="P24">In addition to similarities in cost, plant-derived sources of squalene have been shown to work comparably as an ingredient in adjuvants, and should not require a new approval process for use because they are chemically identical. Therefore, a shift to non-animal-derived squalene is highly feasible without disrupting efforts to rapidly develop a vaccine. A coordinated commitment by the medical sector to transition to non-animal-derived squalene would support both environmental sustainability and public health goals.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Appendix</label>
<media xlink:href="EMS98600-supplement-Supplementary_Appendix.pdf" mimetype="application" mime-subtype="pdf" id="N66264" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S7">
<title>Acknowledgments</title>
<p>We are indebted to Dr. Julia Wester, Dr. David Shiftman, Sonja Fordham, Brandon Theiss, and Dr. Brynn Devine for reading and providing helpful feedback on earlier drafts. Author JS would also like to thank Stefanie Brendl, Alexia Skrbic, and Laurel Irvine for encouraging him to pursue research opportunities associated with this project as part of his internship with Shark Allies.</p>
<sec id="S8">
<title>Funding</title>
<p>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p>
</sec>
</ack>
<ref-list>
<title>Works Cited</title>
<ref id="R1">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Abel</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Grubbs</surname>
<given-names>RD</given-names>
</name>
</person-group>
<source>Shark Biology and Conservation: Essentials for Educators, Students, and Enthusiasts</source>
<publisher-name>John Hopkins University Press</publisher-name>
<publisher-loc>Baltimore MD</publisher-loc>
<year>2020</year>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Myoung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)</article-title>
<source>Journal of Microbiology and Biotechnology</source>
<year>2020</year>
<volume>30</volume>
<issue>3</issue>
<fpage>313</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.4014/jmb.2003.03011</pub-id>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sinan</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Shark ban in its infancy: Successes, challenges and lessons learned</article-title>
<source>Journal of the Marine Biological Association of India</source>
<year>2014</year>
<volume>56</volume>
<issue>1</issue>
<fpage>34</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.6024/jmbai.2014.56.1.01750s-05</pub-id>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Waheed</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Management of shark fisheries in the Maldives, in Shotton, R. (Ed.), Case studies of the management of elasmobranch fisheries</article-title>
<year>1999</year>
<date-in-citation>accessed 2020 Sep 10</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.fao.org/3/X2097E/X2097E17.htm">http://www.fao.org/3/X2097E/X2097E17.htm</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakes</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Lipid, fatty acid and squalene composition of liver oil from six species of deep-sea sharks collected in southern Australian waters</article-title>
<source>Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology</source>
<year>1995</year>
<volume>110</volume>
<issue>1</issue>
<fpage>267</fpage>
<lpage>75</lpage>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brito</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baudner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gallorini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>O’Hagan</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>An alternative renewable source of squalene for use in emulsion adjuvants</article-title>
<source>Vaccine</source>
<year>2011</year>
<volume>29</volume>
<issue>37</issue>
<fpage>6262</fpage>
<lpage>6268</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.067</pub-id>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brito</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>O’Hagan</surname>
<given-names>DT</given-names>
</name>
</person-group>
<article-title>Designing and building the next generation of improved vaccine adjuvants</article-title>
<source>Journal of Controlled Release</source>
<year>2014</year>
<volume>190</volume>
<fpage>563</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="doi">10.1016/j.jconrel.2014.06.027</pub-id>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bontempo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ziller</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Piangiolino</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Morchio</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane: Distinguishing olive oil from shark squalene-squalane</article-title>
<source>Rapid communications in mass spectrometry</source>
<year>2010</year>
<volume>24</volume>
<issue>12</issue>
<fpage>1810</fpage>
<lpage>1816</lpage>
<pub-id pub-id-type="doi">10.1002/rcm.4581</pub-id>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardeñosa</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Genetic identification of threatened shark species in pet food and beauty care products</article-title>
<source>Conservation Genetics</source>
<year>2019</year>
<volume>20</volume>
<issue>6</issue>
<fpage>1383</fpage>
<lpage>1387</lpage>
<pub-id pub-id-type="doi">10.1007/s10592-019-01221-0</pub-id>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardeñosa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abercrombie</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Feldheim</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shea</surname>
<given-names>SKH</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>A multiplex PCR mini-barcode assay to identify processed shark products in the global trade</article-title>
<source>PLoS ONE</source>
<year>2017</year>
<volume>12</volume>
<issue>10</issue>
<fpage>e0185368</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0185368</pub-id>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<source>Current Good Manufacturing Practice for Finished Pharmaceuticals</source>
<year>2019</year>
<comment>21 C.F.R. § 211.84</comment>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Ducos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guillonneau</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Le Manach</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nouvian</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Beauty and the beast: Shark in our beauty creams</article-title>
<year>2015</year>
<date-in-citation>accessed 22 Jun 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.bloomassociation.org/en/wp-content/uploads/2018/04/squalane-bloom-english-1.pdf">http://www.bloomassociation.org/en/wp-content/uploads/2018/04/squalane-bloom-english-1.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="web">
<article-title>Consumers unaware of endangered shark liver oil in cosmetics</article-title>
<source>Oceana EU</source>
<year>2013</year>
<date-in-citation>accessed 28 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://eu.oceana.org/en/press-center/press-releases/consumers-unaware-endangered-shark-liver-oil-cosmetics">https://eu.oceana.org/en/press-center/press-releases/consumers-unaware-endangered-shark-liver-oil-cosmetics</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="web">
<article-title>COVID-19 Could Become a Seasonal Illness: What We’ll Need to Do</article-title>
<source>Healthline</source>
<year>2020</year>
<date-in-citation>accessed 5 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.healthline.com/health-news/covid19-could-become-seasonal-just-like-the-flu">https://www.healthline.com/health-news/covid19-could-become-seasonal-just-like-the-flu</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="web">
<collab>COVID-19 Update</collab>
<year>2020</year>
<date-in-citation>access 4 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.seqirus.com/news/covid19-update">https://www.seqirus.com/news/covid19-update</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Krawchuk</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dulvy</surname>
<given-names>NK</given-names>
</name>
</person-group>
<article-title>Why have global shark and ray landings declined: improved management or overfishing?</article-title>
<source>Fish and Fisheries</source>
<year>2016</year>
<volume>17</volume>
<issue>2</issue>
<fpage>438</fpage>
<lpage>458</lpage>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dent</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>State of the global market for shark products</article-title>
<source>FAO Fisheries and Aquaculture Technical Paper</source>
<year>2015</year>
<volume>590</volume>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deprez</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Volkman</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Squalene content and neutral lipis composition of Livers from Deep-sea sharks caught in Tasmanian waters</article-title>
<source>Marine and Freshwater Research</source>
<year>1990</year>
<volume>41</volume>
<issue>3</issue>
<fpage>375</fpage>
<lpage>87</lpage>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dulvy</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Musick</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cavanagh</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Kyne</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Fordham</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>MP</given-names>
</name>
<etal/>
</person-group>
<article-title>Extinction risk and conservation of the world’s sharks and rays</article-title>
<source>eLife</source>
<year>2014</year>
<volume>3</volume>
<fpage>e00590</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.00590</pub-id>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Dulvy</surname>
<given-names>NK</given-names>
</name>
</person-group>
<article-title>The Global Shark Trends Project: A New Era for the IUCN SSC Shark Specialist Group</article-title>
<year>2018</year>
<date-in-citation>accessed 5 October 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.iucnssg.org/a-new-era-for-the-iucn-ssc-shark-specialist-group.html">https://www.iucnssg.org/a-new-era-for-the-iucn-ssc-shark-specialist-group.html</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Ellis</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>COVID-19 Vaccine Will Probably Require Two Doses</article-title>
<year>2020</year>
<date-in-citation>accessed 5 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.webmd.com/lung/news/20200605/covid-19-vaccine-will-probably-require-two-doses">https://www.webmd.com/lung/news/20200605/covid-19-vaccine-will-probably-require-two-doses</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="web">
<collab>Food &amp; Agricultural Organization (FAO)</collab>
<article-title>Codex general standard for the labelling of prepackaged foods</article-title>
<year>2001</year>
<date-in-citation>accessed 11 Sep 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.fao.org/3/Y2770E/y2770e02.htm">http://www.fao.org/3/Y2770E/y2770e02.htm</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="web">
<collab>[dataset] FAO</collab>
<article-title>FishStatJ—software for fishery statistical time series</article-title>
<year>2020</year>
<date-in-citation>accessed 4 Oct 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.fao.org/fishery/statistics/software/fishstatj/en">http://www.fao.org/fishery/statistics/software/fishstatj/en</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Fowler</surname>
<given-names>ESL</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Dipper</surname>
<given-names>FA</given-names>
</name>
</person-group>
<source>Elasmobranch Biodiversity, Conservation and Management: Proceedings of the International Seminar and Workshop, Sabah, Malaysia, July 1997</source>
<publisher-name>IUCN SSC Shark Specialist Group</publisher-name>
<publisher-loc>IUCN, Gland, Switzerland and Cambridge, UK</publisher-loc>
<year>1997</year>
<comment>xv + 258 pp</comment>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="web">
<collab>GlaxoSmithKline aims</collab>
<article-title>GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners</article-title>
<year>2020</year>
<date-in-citation>accessed 4 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.fiercepharma.com/manufacturing/glaxosmithkline-aims-to-make-1b-doses-vaccine-booster-for-multiple-covid-19-partners">https://www.fiercepharma.com/manufacturing/glaxosmithkline-aims-to-make-1b-doses-vaccine-booster-for-multiple-covid-19-partners</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hareide</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fordham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pinho</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Serena</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Raymakers</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>European Shark Fisheries: A Preliminary Investigation into Fisheries, Conversion Factors, Trade Products, Markets and Management Measures</article-title>
<source>European Elasmobranch Association</source>
<year>2007</year>
<date-in-citation>accessed 2020 Sep 27</date-in-citation>
<comment>27 Sep 2020, <ext-link ext-link-type="uri" xlink:href="http://sasamaconsulting.com/en/pdf/Hareide_2007.pdf">http://sasamaconsulting.com/en/pdf/Hareide_2007.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodgson</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The pandemic pipeline</article-title>
<source>Nature Biotechnology</source>
<year>2020</year>
<volume>38</volume>
<issue>5</issue>
<fpage>523</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1038/d41587-020-00005-z</pub-id>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Keitel</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Kotloff</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Atmar</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Creech</surname>
<given-names>CB</given-names>
</name>
<etal/>
</person-group>
<article-title>Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial</article-title>
<source>JAMA</source>
<year>2015</year>
<volume>314</volume>
<issue>3</issue>
<fpage>237</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2015.7916</pub-id>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreuzer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Shark utilization and marketing</article-title>
<source>FAO Rome</source>
<year>1978</year>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyne</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Simpfendorfer</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>A collation and summarization of available data on deepwater Chondrichthyans: biodiversity, life history and fisheries</article-title>
<source>A report prepared by the IUCN SSC Shark Specialist Group for the Marine Conservation Biology Institute</source>
<year>2007</year>
<date-in-citation>accessed 5 Oct 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.iucnssg.org/uploads/5/4/1/2/54120303/deepwater_chondrichthyans.pdf">href="https://www.iucnssg.org/uploads/5/4/1/2/54120303/deepwater_chondrichthyans.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Karadeniz</surname>
<given-names>F</given-names>
</name>
</person-group>
<chapter-title>Biological Importance and Applications of Squalene and Squalane</chapter-title>
<source>in Advances in Food and Nutrition Research</source>
<publisher-name>Academic Press</publisher-name>
<year>2012</year>
<volume>65</volume>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Lack</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sant</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Trends in Global Shark Catch and Recent Developments in Management. Traffic International</article-title>
<year>2009</year>
<date-in-citation>accessed 4 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.traffic.org/publications/reports/trends-in-global-shark-catch/">https://www.traffic.org/publications/reports/trends-in-global-shark-catch/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lozano-Grande</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gorinstein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Espitia-Rangel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dávila-Ortiz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martínez-Ayala</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Plant Sources, Extraction Methods, and Uses of Squalene</article-title>
<source>International Journal of Agronomy</source>
<year>2018</year>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1155/2018/1829160</pub-id>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musick</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bonfil</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Shark Utilization, in Musick, J.A., Management Techniques for elasmobranch fisheries</article-title>
<source>FAO Fisheries Technical Paper</source>
<year>2005</year>
<volume>474</volume>
<fpage>243</fpage>
<lpage>251</lpage>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="web">
<collab>National Center for Biotechnology Information</collab>
<article-title>PubChem Compound Summary for CID 638072, Squalene</article-title>
<year>2020</year>
<comment>Retrieved October 13, 2020 from <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Squalene">https://pubchem.ncbi.nlm.nih.gov/compound/Squalene</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neiva</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coelho</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Erzini</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Feeding habits of the velvet belly lanternshark Etmopterus spinax (Chondrichthyes: Etmopteridae) off the Algarve, southern Portugal. Marine Biological Association of the United Kingdom</article-title>
<source>Journal of the Marine Biological Association of the United Kingdom</source>
<year>2006</year>
<volume>86</volume>
<issue>4</issue>
<fpage>835</fpage>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Nichols</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rayner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>A pilot investigation of Northern Australian shark liver oils: characterization and value-adding</article-title>
<source>CSIRO Marine Research</source>
<year>2001</year>
<date-in-citation>accessed 5 Oct 2020</date-in-citation>
<comment>FRDC Project 99/369, <ext-link ext-link-type="uri" xlink:href="http://frdc.com.au/Archived-Reports/FRDC%20Projects/1999-369-DLD.pdf">http://frdc.com.au/Archived-Reports/FRDC%20Projects/1999-369-DLD.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panatto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haag</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Tomczyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amicizia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lino</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59®-adjuvanted influenza vaccine in older adults: Results from three consecutive seasons</article-title>
<source>Influenza Other Respiratory Viruses</source>
<year>2020</year>
<volume>14</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1111/irv.12685</pub-id>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rawn</surname>
<given-names>DFK</given-names>
</name>
<name>
<surname>Krakalovich</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Forsyth</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Roscoe</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Analysis of fin and non-fin fish products for azamethiphos and dichlorvos residues from the Canadian retail market</article-title>
<source>International Journal of Food Science &amp; Technology</source>
<year>2009</year>
<volume>44</volume>
<issue>8</issue>
<fpage>1510</fpage>
<lpage>1516</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2621.2007.01678.x</pub-id>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Holznagel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alex</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sawatsky</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Enkirch</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pfeffermann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kruip</surname>
<given-names>C</given-names>
</name>
<name>
<surname>von Messling</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtypespecific antibodies against the neuraminidase</article-title>
<source>Vaccine</source>
<year>2016</year>
<volume>34</volume>
<issue>44</issue>
<fpage>5329</fpage>
<lpage>5335</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.08.082</pub-id>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schultze</surname>
<given-names>V</given-names>
</name>
<name>
<surname>D’Agosto</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wack</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Novicki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zorn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hennig</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Safety of MF59(TM) adjuvant</article-title>
<source>Vaccine</source>
<year>2008</year>
<volume>26</volume>
<issue>26</issue>
<fpage>3209</fpage>
<lpage>3222</lpage>
<date-in-citation>10.1016/j.vaccine.2008.03.093</date-in-citation>
</element-citation>
</ref>
<ref id="R42">
<element-citation publication-type="web">
<collab>Shark Free</collab>
<article-title>Shark Free – Shark Angels</article-title>
<source>Shark Angels</source>
<date-in-citation>accessed 28 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://sharkangels.org/what-we-do/shark-free">https://sharkangels.org/what-we-do/shark-free</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiffman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Bittick</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cashion</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Colla</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Coristine</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Derrick</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Gow</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>More O’Ferrall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Orobko</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Inaccurate and Biased Global Media Coverage Underlies Public Misunderstanding of Shark Conservation Threats and Solutions</article-title>
<source>iScience</source>
<year>2020</year>
<volume>23</volume>
<issue>6</issue>
<comment>101205</comment>
<pub-id pub-id-type="doi">10.1016/j.isci.2020.101205</pub-id>
</element-citation>
</ref>
<ref id="R44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibuyo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Widiputri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Legowo</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Optimization of squalene extraction from Palm Fatty Acid Distillate (PFAD) in multistage process</article-title>
<source>AIP Conference Proceedings</source>
<year>2017</year>
<volume>1803</volume>
<issue>1</issue>
<comment>020060</comment>
<pub-id pub-id-type="doi">10.1063/1.4973187</pub-id>
</element-citation>
</ref>
<ref id="R45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpfendorfer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Kyne</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Limited potential to recover from overfishing raises concerns for deep-sea sharks, rays and chimaeras</article-title>
<source>Environmental Conservation</source>
<year>2009</year>
<volume>36</volume>
<issue>2</issue>
<fpage>97</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1017/S0376892909990191</pub-id>
</element-citation>
</ref>
<ref id="R46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stadler</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eickmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kolesnikova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Klenk</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rappuoli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Abrignani</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS Vaccine Protective in Mice</article-title>
<source>Emerging Infectious Diseases</source>
<year>2005</year>
<volume>11</volume>
<issue>8</issue>
<fpage>1312</fpage>
<lpage>1314</lpage>
<pub-id pub-id-type="doi">10.3201/eid1108.041003</pub-id>
</element-citation>
</ref>
<ref id="R47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bonfil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dulvy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The effects of fishing on sharks, rays, and chimaeras (Chondrichthyans), and the implications for marine ecosystems</article-title>
<source>ICES Journal of Marine Science</source>
<year>2000</year>
<volume>57</volume>
<fpage>476</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1006/jmsc.2000.0724</pub-id>
</element-citation>
</ref>
<ref id="R48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>CTK</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus</article-title>
<source>Human vaccines &amp; immunotherapeutics</source>
<year>2015</year>
<volume>11</volume>
<issue>5</issue>
<fpage>1244</fpage>
<lpage>1250</lpage>
<pub-id pub-id-type="doi">10.1080/21645515.2015.1021527</pub-id>
</element-citation>
</ref>
<ref id="R49">
<element-citation publication-type="web">
<collab>U.S. to Stockpile</collab>
<article-title>U.S. to stockpile vaccine candidates as trials continue: health secretary</article-title>
<source>Reuters</source>
<year>2020</year>
<date-in-citation>accessed 5 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.reuters.com/article/us-health-coronavirus-usa-vaccine-idUSKBN22R2C0">https://www.reuters.com/article/us-health-coronavirus-usa-vaccine-idUSKBN22R2C0</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R50">
<element-citation publication-type="web">
<collab>Vaccine companies</collab>
<article-title>Vaccine companies searching for 1-shot dose of COVID-19 vaccine</article-title>
<source>ABC News</source>
<year>2020</year>
<date-in-citation>accessed 5 Aug 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://abcnews.go.com/Health/vaccine-companies-searching-shot-dose-covid-19-vaccine/story?id=72053977">https://abcnews.go.com/Health/vaccine-companies-searching-shot-dose-covid-19-vaccine/story?id=72053977</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R51">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Vannuccini</surname>
<given-names>S</given-names>
</name>
</person-group>
<source>Shark utilization, marketing and trade (No. 389)</source>
<publisher-name>FAO FISHERIES TECHNICAL PAPER</publisher-name>
<year>1999</year>
<volume>389</volume>
<date-in-citation>accessed 29 Jun 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.fao.org/3/x3690e/x3690e1d.htm">http://www.fao.org/3/x3690e/x3690e1d.htm</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veríssimo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacMillan</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Toward a systematic approach for identifying conservation flagships: Identifying conservation flagships</article-title>
<source>Conservation Letters</source>
<year>2011</year>
<volume>4</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-263X.2010.00151.x</pub-id>
</element-citation>
</ref>
<ref id="R53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vesikari</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pepin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kusters</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hoffenbach</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age</article-title>
<source>Human vaccines &amp; immunotherapeutics</source>
<year>2012</year>
<volume>8</volume>
<issue>9</issue>
<fpage>1283</fpage>
<lpage>1292</lpage>
<pub-id pub-id-type="doi">10.4161/hv.21265</pub-id>
</element-citation>
</ref>
<ref id="R54">
<element-citation publication-type="web">
<collab>World Health Organization (WHO)</collab>
<article-title>Draft landscape of COVID-19 candidate vaccines</article-title>
<year>2020</year>
<date-in-citation>accessed 5 Oct 2020</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kettemer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ward-Paige</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heithaus</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kessel</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Global catches, exploitation rates, and rebuilding options for sharks</article-title>
<source>Marine Policy</source>
<year>2013</year>
<volume>40</volume>
<fpage>194</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.marpol.2012.12.034</pub-id>
</element-citation>
</ref>
<ref id="R56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses</article-title>
<source>Vaccine</source>
<year>2014</year>
<volume>32</volume>
<issue>35</issue>
<fpage>4485</fpage>
<lpage>4494</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.043</pub-id>
</element-citation>
</ref>
<ref id="R57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Channappanavar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garron</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tasneem</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>CTK</given-names>
</name>
<etal/>
</person-group>
<article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title>
<source>Cellular &amp; molecular immunology</source>
<year>2016</year>
<volume>13</volume>
<issue>2</issue>
<fpage>180</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Most recent IUCN Red List assessments for assessed elasmobranch species (n=131) reported in the liver oil trade. The earliest assessment of a species identified as traded for liver oil took place in 2003.</p>
</caption>
<graphic xlink:href="EMS98600-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>IUCN Red List conservation status of elasmobranch species reported in the liver oil trade.</p>
</caption>
<graphic xlink:href="EMS98600-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>IUCN Red List population trends of all elasmobranch species reported in the liver oil trade.</p>
</caption>
<graphic xlink:href="EMS98600-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>The total reported net weight (tonnes) of annual trade in shark liver oil reported to FAO. In 2018, two countries reported trade: imports of 33 tonnes (Republic of Korea) and processed production of 719 tonnes (Senegal).</p>
</caption>
<graphic xlink:href="EMS98600-f004"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Estimated number of sharks needed to produce two vaccine doses for the global human population under a range of yield assumptions.</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" rowspan="2">Shark weight (kg)</th>
<th align="center" valign="middle">Liver weight</th>
<th align="center" valign="middle">Liver oil weight</th>
<th align="center" valign="middle">Squalene weight</th>
<th align="center" valign="middle">Total sharks<xref ref-type="table-fn" rid="TFN1">*</xref>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" colspan="1"/>
<td style="border-bottom: solid thin;" align="center" valign="middle" colspan="5">Best case</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="center" valign="top">
<underline>20%</underline>
</td>
<td align="center" valign="top">
<underline>70%</underline>
</td>
<td align="center" valign="top">
<underline>82%</underline>
</td>
<td align="right" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">2.3 kg (small shark)</td>
<td align="right" valign="top">0.46</td>
<td align="right" valign="top">0.32</td>
<td align="right" valign="top">0.26</td>
<td align="right" valign="top">576,049</td>
</tr>
<tr>
<td align="left" valign="top">5.6 kg (deep-sea shark)</td>
<td align="right" valign="top">1.12</td>
<td align="right" valign="top">0.78</td>
<td align="right" valign="top">0.64</td>
<td align="right" valign="top">236,592</td>
</tr>
<tr>
<td align="left" valign="top">20.8 kg shark (median)</td>
<td align="right" valign="top">4.16</td>
<td align="right" valign="top">2.91</td>
<td align="right" valign="top">2.39</td>
<td align="right" valign="top">63, 693</td>
</tr>
<tr>
<td align="left" valign="top">46.2 kg (large shark)</td>
<td align="right" valign="top">9.24</td>
<td align="right" valign="top">6.47</td>
<td align="right" valign="top">5.30</td>
<td align="right" valign="top">28,678</td>
</tr>
<tr>
<td align="center" valign="middle" colspan="1"/>
<td style="border-top: solid thin; border-bottom: solid thin;" align="center" valign="middle" colspan="5">Moderate case</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="center" valign="top">
<underline>10%</underline>
</td>
<td align="center" valign="top">
<underline>40%</underline>
</td>
<td align="center" valign="top">
<underline>50%</underline>
</td>
<td align="right" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">2.3 kg (small shark)</td>
<td align="right" valign="top">0.23</td>
<td align="right" valign="top">0.09</td>
<td align="right" valign="top">0.05</td>
<td align="right" valign="top">3,306,522</td>
</tr>
<tr>
<td align="left" valign="top">20.8 kg shark (median)</td>
<td align="right" valign="top">2.08</td>
<td align="right" valign="top">0.83</td>
<td align="right" valign="top">0.42</td>
<td align="right" valign="top">365,385</td>
</tr>
<tr>
<td align="left" valign="top">46.2 kg (large shark)</td>
<td align="right" valign="top">4.62</td>
<td align="right" valign="top">1.85</td>
<td align="right" valign="top">0.92</td>
<td align="right" valign="top">164,610</td>
</tr>
<tr>
<td align="center" valign="middle" colspan="1"/>
<td style="border-top: solid thin; border-bottom: solid thin;" align="center" valign="middle" colspan="5">Worst case</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="center" valign="top">
<underline>3%</underline>
</td>
<td align="center" valign="top">
<underline>10%</underline>
</td>
<td align="center" valign="top">
<underline>15%</underline>
</td>
<td align="right" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">2.3 kg (small shark)</td>
<td align="right" valign="top">0.069</td>
<td align="right" valign="top">0.007</td>
<td align="right" valign="top">0.00104</td>
<td align="right" valign="top">146,956,522</td>
</tr>
<tr>
<td align="left" valign="top">20.8 kg shark (median)</td>
<td align="right" valign="top">0.624</td>
<td align="right" valign="top">0.062</td>
<td align="right" valign="top">0.00936</td>
<td align="right" valign="top">16,239,316</td>
</tr>
<tr>
<td align="left" valign="top">46.2 kg (large shark)</td>
<td align="right" valign="top">1.386</td>
<td align="right" valign="top">0.139</td>
<td align="right" valign="top">0.02079</td>
<td align="right" valign="top">7,316,017</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>*</label>
<p id="P25">Based on a maximum demand estimate, assuming use of MF59 adjuvant containing 9.75 mg of squalene per dose to provide 2 vaccines to 7.8 billion people, total squalene demand for vaccines (drawn from existing or new fisheries) would be 152,100 kg.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<title>Current listed wholesale prices of shark- and plant-derived squalene and squalane by kg in USD.</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-top: solid thin; border-bottom: solid thin;">
<th align="center" valign="middle" colspan="4">Squalane</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">
<underline>
<italic>Source</italic>
</underline>
</td>
<td align="left" valign="top">
<underline>
<italic>Price/Kg (USD)</italic>
</underline>
</td>
<td align="left" valign="top">
<underline>
<italic>Sold From</italic>
</underline>
</td>
<td align="left" valign="top">
<underline>
<italic>Manufacturer</italic>
</underline>
</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$39-47</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Xi'an Rozen Biotechnology Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$25</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Xa Bc-Biotech Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$54</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Wuhan Hengheda Pharm Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$260</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Haihang Industry Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$35-80</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Xi'an Sheerherb Biological <break/>Technology</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$20-60</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Shandong Zesheng Chemical Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$55</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Shaanxi Phoenix Tree Biotech Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">$20-60</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Suzhou Manson Biotech Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Soybeans</td>
<td align="left" valign="top">$20-60</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Suzhou Manson Biotech Co., Ltd</td>
</tr>
<tr style="border-top: solid thin; border-bottom: solid thin;">
<td align="center" valign="middle" colspan="4">Squalane</td>
</tr>
<tr>
<td align="left" valign="top">
<underline>
<italic>Source</italic>
</underline>
</td>
<td align="left" valign="top">
<underline>
<italic>Price/Kg (USD)</italic>
</underline>
</td>
<td align="left" valign="top">
<underline>
<italic>Sold From</italic>
</underline>
</td>
<td align="left" valign="top">
<underline>
<italic>Manufacturer</italic>
</underline>
</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">~$40</td>
<td align="left" valign="top">USA</td>
<td align="left" valign="top">Jedwards International INC.</td>
</tr>
<tr>
<td align="left" valign="top">Shark</td>
<td align="left" valign="top">$50</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Xa Bc-Biotech Co, Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">$44.89</td>
<td align="left" valign="top">USA</td>
<td align="left" valign="top">Cocojojo Beauty</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">$63.99</td>
<td align="left" valign="top">USA</td>
<td align="left" valign="top">Organic Gold</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">$10-20</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Shandong Zhonglan Chemical Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">$40-60</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Xi'an Geekee Biotech Co., Ltd</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">~$51.75</td>
<td align="left" valign="top">USA</td>
<td align="left" valign="top">Jedwards International INC.</td>
</tr>
<tr>
<td align="left" valign="top">Olive Oil</td>
<td align="left" valign="top">~$47.30</td>
<td align="left" valign="top">USA (Origin Italy, <break/>Spain)</td>
<td align="left" valign="top">Blossom Bulk Ingredients</td>
</tr>
<tr>
<td align="left" valign="top">Neossance (Sugarcane)</td>
<td align="left" valign="top">$99.21</td>
<td align="left" valign="top">USA</td>
<td align="left" valign="top">HBNO</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
